1
|
Tiran AL, Claperon A, Davidson J, Starck JB, Diguarher TL, Chanrion M, Mistry P, Wang Y, Monceau E, Bernhardt F, Rocchetti F, Lysiak-Auvity G, Chen I, Daniels Z, Pedder C, Fallowfield M, Henlin JM, Fejes I, Tatai J, Nyerges M, Durand D, Zarka M, Sanghavi S, Girard AM, Schoumacher M, Kraus-Berthier L, Newcombe R, Halilovic E, Banquet S, Rupin A, Maacke H, Murray J, Morris E, Hofmann F, Colland F, Geneste O. Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Venetoclax (Venclexta™), a selective BCL-2 inhibitor, is the first member of a new class of anti-cancer drugs, called BH3 mimetics, to be approved for CLL and AML. Here, we describe the identification of a novel potent and selective BCL-2 inhibitor named S65487/VOB560 that has a different binding mode on BCL-2 compared to Venetoclax. This inhibitor binds to the BH3 hydrophobic groove of BCL-2. Its selectivity profile demonstrates lack of significant binding to MCL-1, BFL-1 and poor affinity for BCL-XL. S65487/VOB560 induces apoptosis in a panel of hematological cancer cell lines and inhibits cell proliferation with IC50s in the low nM range. S65487/VOB560 induces complete regression in BCL-2-dependent RS4;11 tumors in vivo after a single IV (intravenous) administration. Strong and persistent tumor regression in xenograft models of lymphoid malignancies in mouse and rat were observed at well tolerated doses following weekly IV administration of S65487 in combination with the MCL-1-specific inhibitor, S64315/MIK665. These positive findings were further confirmed in a panel of AML PDX tumor models. Recently, acquired BCL-2 mutations (such as G101V and D103Y) were identified in patients with Chronic Lymphocytic Leukemia becoming resistant to Venetoclax. Interestingly, S65487/VOB560 is active on such BCL-2 mutants and induces apoptosis in preclinical resistance models. Altogether, these data demonstrate that S65487/VOB560 has significant therapeutic potential against human lymphoid and myeloid malignancies as well as in patients with Venetoclax resistant leukemias. Clinical studies are currently ongoing with S65487/VOB560 (NCT03755154).
Citation Format: Arnaud Le Tiran, Audrey Claperon, James Davidson, Jérôme-Benoit Starck, Thierry Le Diguarher, Maïa Chanrion, Prakash Mistry, Youzhen Wang, Elodie Monceau, Fabienne Bernhardt, Francesca Rocchetti, Gaelle Lysiak-Auvity, Ijen Chen, Zoe Daniels, Chris Pedder, Mandy Fallowfield, Jean-Michel Henlin, Imre Fejes, Janos Tatai, Miklos Nyerges, Didier Durand, Marion Zarka, Sneha Sanghavi, Anne-Marie Girard, Marie Schoumacher, Laurence Kraus-Berthier, Rick Newcombe, Ensar Halilovic, Sébastien Banquet, Alain Rupin, Heiko Maacke, James Murray, Erick Morris, Francesco Hofmann, Frédéric Colland, Olivier Geneste. Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1276.
Collapse
Affiliation(s)
- Arnaud Le Tiran
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Audrey Claperon
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | | | - Jérôme-Benoit Starck
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Thierry Le Diguarher
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Maïa Chanrion
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Prakash Mistry
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | - Youzhen Wang
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Elodie Monceau
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Fabienne Bernhardt
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Francesca Rocchetti
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | | | - Ijen Chen
- 3Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | - Zoe Daniels
- 3Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | | | | | - Jean-Michel Henlin
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Imre Fejes
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Janos Tatai
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Miklos Nyerges
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Didier Durand
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Marion Zarka
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Sneha Sanghavi
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Anne-Marie Girard
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Marie Schoumacher
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | | | - Rick Newcombe
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Ensar Halilovic
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Sébastien Banquet
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Alain Rupin
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Heiko Maacke
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | | | - Erick Morris
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Francesco Hofmann
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | - Frédéric Colland
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Olivier Geneste
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| |
Collapse
|
2
|
Maragno AL, Mistry P, Kotschy A, Szlavik Z, Murray J, Davidson J, Toumelin-Braizat GL, Chanrion M, Bruno A, Claperon A, Maacke H, Morris E, Wang Y, Derreal A, Csekei M, Paczal A, Szabo Z, Sipos S, Proszenyak A, Balint B, Surgenor A, Dokurno P, Matassova N, Chen I, Lysiak-Auvity G, Girard AM, Grave F, Colland F, Halilovic E, Geneste O. Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4482] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mcl-1 is highly expressed in a variety of human cancers (including those of hematopoietic and lymphoid origin) and is exploited by cancer cells to evade cell death and to develop resistance to diverse chemotherapeutic agents. We disclose, for the first time, the structure of S64315 (also named MIK665) a highly potent and selective inhibitor of Mcl-1 with improved potency over its predecessor S63845 (Kotschy et al, Nature, 2016). S64315/MIK665 is currently in phase 1 in AML (Acute Myeloid Leukemia) and MDS (Myelodysplastic Syndrome) (EudraCT 2016-003768-38, NCT 02979366) and in MM (Multiple Myeloma) and lymphoma (NCT02992483). A fragment-based, structure-guided drug discovery effort led to the identification of S64315/MIK665 that binds to human Mcl-1 with a sub-nanomolar affinity (Ki 0.048 nM) and selectively over other anti-apoptotic Bcl-2 family members. It has similar affinity for human, rat, dog and monkey Mcl-1 but about a ten-fold lower affinity for mouse Mcl-1. S64315/MIK665 causes dose-dependent activation of the intrinsic apoptosis pathway in a Bax/Bak-dependent manner, as measured by increased caspase activity and cleaved PARP. S64315/MIK665 shows strong cell killing activity in a diverse panel of human hematological tumor cell lines, including AML, lymphoma and MM. The activity profile of S64315/MIK665 is distinct from that of venetoclax, a selective Bcl2 inhibitor. In vivo, S64315 as single agent demonstrated potent and dose-dependent apoptotic and antitumor response after intravenous administration in several human hematological tumor models grafted in immuno-compromised mice and rats. Complete regression of established tumors, at well tolerated doses, was achieved using different intravenous dosing regimens in rats as well as in mice. Finally, dual BH3-mimetic targeting approach combining S64315/MIK665 with BCL2 inhibitors showed strong and durable antitumor responses in several hematological tumor models both in vitro and in vivo.
Citation Format: Ana Leticia Maragno, Prakash Mistry, András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Alain Bruno, Audrey Claperon, Heiko Maacke, Erick Morris, Youzhen Wang, Alix Derreal, Márton Csekei, Attila Paczal, Zoltán Szabo, Szabolcs Sipos, Agnes Proszenyak, Balázs Balint, Allan Surgenor, Pawel Dokurno, Natalia Matassova, Ijen Chen, Gaëlle Lysiak-Auvity, Anne-Marie Girard, Fabienne Grave, Frédéric Colland, Ensar Halilovic, Olivier Geneste. S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4482.
Collapse
Affiliation(s)
| | - Prakash Mistry
- 2Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - András Kotschy
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Zoltán Szlavik
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | | | | | | | - Maïa Chanrion
- 1Institut de Recherche Servier, Croissy sur Seine, France
| | - Alain Bruno
- 5Institut de Recherches Internationales Servier, Suresnes, France
| | | | - Heiko Maacke
- 2Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Erick Morris
- 6Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Youzhen Wang
- 6Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Alix Derreal
- 5Institut de Recherches Internationales Servier, Suresnes, France
| | - Márton Csekei
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Attila Paczal
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Zoltán Szabo
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Szabolcs Sipos
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Agnes Proszenyak
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Balázs Balint
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | | | | | | | - Ijen Chen
- 4Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | | | | | - Fabienne Grave
- 1Institut de Recherche Servier, Croissy sur Seine, France
| | | | | | | |
Collapse
|
3
|
Wang Y, Qui S, Sanghavi S, Mulford I, Lysiak G, Chanrion M, Mistry P, Pfaar U, Schoumacher M, Claperon A, Kraus-Berthier L, Banquet S, Derreal A, Fabre C, Maacke H, Colland F, Geneste O, Morris E, Halilovic E. Abstract 257: Targeting AML through apoptosis activation using Bcl-2/Mcl-1 or Bcl-2/Hdm2 inhibitor combination therapies. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematologic malignancy, characterized by uncontrolled proliferation and impaired differentiation of myeloid cells. With the exception of certain subtypes, the average long-term survival rate remains low, thus underlining the need to further improve the outcome of AML patients. Since AML is one of the least mutated cancer types, the majority of AML patients may not carry targetable genetic alterations. However, the anti-apoptotic proteins of the Bcl-2 family, such as Bcl-2 and Mcl-1, are often overexpressed in AML, allowing deregulated survival; hence pro-apoptosis priming with small molecule inhibitors of Bcl-2 and Mcl-1 may provide a broader therapeutic benefit across the disease. In addition, a majority of AML patients carry wild-type p53, providing therapeutic opportunity for Hdm2 inhibitors to stabilize p53 and lead to expression of pro-apoptotic molecules (e.g., PUMA & BAX). Therefore, targeting the combined apoptosis mechanisms by inhibiting different anti-apoptotic Bcl-2 family of proteins and activating p53 concomitantly may synergistically enhance apoptotic cell death of AML tumor cells.
We tested the combination of Bcl-2 inhibitors (BCL201/S55746 or venetoclax) with either MIK665/S64315, a novel and selective inhibitor of Mcl-1 or HDM201, a selective small molecule inhibitor of p53:Hdm2 interaction, in a series of in vitro and in vivo studies in AML. In vitro, strong combination synergy was observed with a remarkable induction of cell death for both combinations. In vivo, the combination of Bcl-2 inhibitors with MIK665/S64315 or HDM201 lead to complete and durable antitumor responses in a variety of p53wt AML patient-derived xenograft models of heterogeneous genetic profiles. Notably, lowering the dose of HDM201 by 4 fold from its most efficacious dose, resulted in a high degree of tumor regressions while mitigating the toxicity effects on platelets. Taken together, these data demonstrate that a combination of Bcl-2 inhibitor (BCL201/S55746 or venetoclax) with MIK665/S64315 or HDM201 provide therapeutic benefit over the monotherapy, and support a rationale for testing these apoptosis enhancing combination approaches in AML patients.
Citation Format: Youzhen Wang, Shumei Qui, Sneha Sanghavi, Iain Mulford, Gaëlle Lysiak, Maïa Chanrion, Prakash Mistry, Ulrike Pfaar, Marie Schoumacher, Audrey Claperon, Laurence Kraus-Berthier, Sébastien Banquet, Alix Derreal, Claire Fabre, Heiko Maacke, Frédéric Colland, Olivier Geneste, Erick Morris, Ensar Halilovic. Targeting AML through apoptosis activation using Bcl-2/Mcl-1 or Bcl-2/Hdm2 inhibitor combination therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 257.
Collapse
Affiliation(s)
- Youzhen Wang
- 1Novartis Insts. for BioMedical Research, Cambridge, MA
| | - Shumei Qui
- 1Novartis Insts. for BioMedical Research, Cambridge, MA
| | | | - Iain Mulford
- 1Novartis Insts. for BioMedical Research, Cambridge, MA
| | - Gaëlle Lysiak
- 2Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Maïa Chanrion
- 2Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Prakash Mistry
- 3Novartis Insts. for BioMedical Research, Basel, Switzerland
| | - Ulrike Pfaar
- 3Novartis Insts. for BioMedical Research, Basel, Switzerland
| | | | | | | | | | | | - Claire Fabre
- 3Novartis Insts. for BioMedical Research, Basel, Switzerland
| | - Heiko Maacke
- 3Novartis Insts. for BioMedical Research, Basel, Switzerland
| | | | | | - Erick Morris
- 1Novartis Insts. for BioMedical Research, Cambridge, MA
| | | |
Collapse
|
4
|
Halilovic E, Chanrion M, Mistry P, Wartmann M, Qiu S, Sanghavi S, Chen Y, Lysiak G, Maragno AL, Pfaar U, Huth F, Schoumacher M, Claperon A, Kraus-Berthier L, Banquet S, Derreal A, Maacke H, Colland F, Geneste O, Morris E, Wang Y. Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4477] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
One of the hallmarks of cancer is evasion of apoptosis. The B-cell lymphoma-2 (Bcl-2) family of proteins represents a crucial point of control of apoptosis. The Bcl-2 family comprises both pro- and anti-apoptotic members, the latter of which (Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and Bcl-2A1) are often overexpressed in cancer cells, supporting their aberrant survival. Thus, these anti-apoptotic proteins have become an attractive target for cancer therapy. BH3 mimetics have been shown to bind to the BH3 binding groove of anti-apoptotic Bcl-2 family members and inhibit their function, resulting in apoptotic cell death, and one such BH3 mimetic, ABT-199 (venetoclax), has recently been approved for treatment of relapsed or refractory Chronic Lymphocytic Leukemia. We have developed two novel and potent BH3 mimetics: MIK665/S64315, a highly selective inhibitor of Mcl-1 and BCL201/S55746, a selective Bcl-2 inhibitor. Both compounds, individually induce apoptosis in hematological cancer cell lines, primary patient samples and demonstrate anti-tumor efficacy in xenograft models. MIK665/S64315 is currently in phase 1 clinical development in AML and MDS (NCT 02979366) and in MM and lymphoma (NCT02992483). Here, we describe the activity of the combination of MIK665/S64315 with BCL201/S55746 or venetoclax, both in vitro and in vivo, across a range of hematological indications (AML, MM and DLBCL). In vitro, a strong synergy was observed with these combinations, resulting in a remarkable induction of cell death in majority of cell lines tested. In vivo, MIK665/S64315 and BCL201/S55746 combinations lead to complete and durable antitumor responses in many different xenograft models in mice and rats. Taken together, these data demonstrate that a combination of MIK665/S64315 and BCL201/S55746 provide strong therapeutic benefit over either monotherapy, and support a rationale for testing Mcl-1 and Bcl-2 inhibitor combinations in patients with hematological malignancies.
Citation Format: Ensar Halilovic, Maïa Chanrion, Prakash Mistry, Markus Wartmann, Shumei Qiu, Sneha Sanghavi, Yan Chen, Gaëlle Lysiak, Ana Leticia Maragno, Ulrike Pfaar, Felix Huth, Marie Schoumacher, Audrey Claperon, Laurence Kraus-Berthier, Sébastien Banquet, Alix Derreal, Heiko Maacke, Frédéric Colland, Olivier Geneste, Erick Morris, Youzhen Wang. MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4477.
Collapse
Affiliation(s)
| | - Maïa Chanrion
- 2Servier Oncology R&D Unit, Croissy-sur-seine, France
| | - Prakash Mistry
- 3Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Markus Wartmann
- 3Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Shumei Qiu
- 1Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Sneha Sanghavi
- 1Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Yan Chen
- 1Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Gaëlle Lysiak
- 2Servier Oncology R&D Unit, Croissy-sur-seine, France
| | | | - Ulrike Pfaar
- 3Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Felix Huth
- 3Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | | | | | | | | | - Heiko Maacke
- 3Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | | | - Erick Morris
- 1Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Youzhen Wang
- 1Novartis Institutes for BioMedical Research, Cambridge, MA
| |
Collapse
|
5
|
Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med 2018; 9:9/401/eaam7049. [PMID: 28768804 DOI: 10.1126/scitranslmed.aam7049] [Citation(s) in RCA: 127] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 04/13/2017] [Accepted: 06/29/2017] [Indexed: 12/15/2022]
Abstract
The development of BH3 mimetics, which antagonize prosurvival proteins of the BCL-2 family, represents a potential breakthrough in cancer therapy. Targeting the prosurvival member MCL-1 has been an area of intense interest because it is frequently deregulated in cancer. In breast cancer, MCL-1 is often amplified, and high expression predicts poor patient outcome. We tested the MCL-1 inhibitor S63845 in breast cancer cell lines and patient-derived xenografts with high expression of MCL-1. S63845 displayed synergistic activity with docetaxel in triple-negative breast cancer and with trastuzumab or lapatinib in HER2-amplified breast cancer. Using S63845-resistant cells combined with CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 (CRISPR-associated 9) technology, we identified deletion of BAK and up-regulation of prosurvival proteins as potential mechanisms that confer resistance to S63845 in breast cancer. Collectively, our findings provide a strong rationale for the clinical evaluation of MCL-1 inhibitors in breast cancer.
Collapse
Affiliation(s)
- Delphine Merino
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - James R Whittle
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - François Vaillant
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Antonin Serrano
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Jia-Nan Gong
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - Goknur Giner
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - Ana Leticia Maragno
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine 78290, France
| | - Maïa Chanrion
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine 78290, France
| | - Emilie Schneider
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine 78290, France
| | - Bhupinder Pal
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Xiang Li
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Cell Signalling and Cell Death Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - Grant Dewson
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Cell Signalling and Cell Death Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - Julius Gräsel
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Kevin Liu
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Najoua Lalaoui
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Cell Signalling and Cell Death Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - David Segal
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - Marco J Herold
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - David C S Huang
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
| | - Gordon K Smyth
- Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,School of Mathematics and Statistics, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Olivier Geneste
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine 78290, France
| | - Guillaume Lessene
- Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.,Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.,Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Jane E Visvader
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. .,Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Geoffrey J Lindeman
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. .,Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.,Department of Medicine, University of Melbourne, Parkville, Victoria 3010, Australia.,Parkville Familial Cancer Centre, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Victoria 3050, Australia
| |
Collapse
|
6
|
Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard AM, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin JM, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJ, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget 2018; 9:20075-20088. [PMID: 29732004 PMCID: PMC5929447 DOI: 10.18632/oncotarget.24744] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 02/26/2018] [Indexed: 12/15/2022] Open
Abstract
Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion. Here, we describe a novel orally bioavailable BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). S55746 occupies the hydrophobic groove of BCL-2. Its selectivity profile demonstrates no significant binding to MCL-1, BFL-1 (BCL2A1/A1) and poor affinity for BCL-XL. Accordingly, S55746 has no cytotoxic activity on BCL-XL-dependent cells, such as platelets. In a panel of hematological cell lines, S55746 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo, S55746 induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, S55746 administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior. Taken together, these data demonstrate that S55746 is a novel, well-tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein.
Collapse
Affiliation(s)
- Patrick Casara
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | | | - Audrey Claperon
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Meike Vogler
- Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany
| | - Alain Bruno
- Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Maïa Chanrion
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Thierry Le Diguarher
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | - Jérôme-Benoît Starck
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | | | | | | | | | | | | | - Youzhen Wang
- Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA
| | - Shumei Qiu
- Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA
| | - Anne-Marie Girard
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Emilie Schneider
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Fabienne Gravé
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Aurélie Studeny
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Ghislaine Guasconi
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Sophie Maïga
- CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France
| | - Jean-Michel Henlin
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | - Frédéric Colland
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Steven Le Gouill
- CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France
| | - Martin J.S. Dyer
- Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK
| | | | | | - Martine Amiot
- CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France
| | - Gerald M Cohen
- Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - John A. Hickman
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Erick Morris
- Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA
| | | | - Olivier Geneste
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| |
Collapse
|
7
|
Docquier A, Harmand PO, Fritsch S, Chanrion M, Darbon JM, Cavaillès V. The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res 2010; 16:2959-70. [PMID: 20410059 DOI: 10.1158/1078-0432.ccr-09-3153] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
PURPOSE Receptor-interacting protein of 140 kDa (RIP140) is a transcriptional cofactor for nuclear receptors involved in reproduction and energy homeostasis. Our aim was to investigate its role in the regulation of E2F1 activity and target genes both in breast cancer cell lines and in tumor biopsies. EXPERIMENTAL DESIGN Glutathione S-transferase pull-down assays, coimmunoprecipitation experiments, and chromatin immunoprecipitation analysis were used to evidence interaction between RIP140 and E2F1. The effects of RIP140 expression on E2F1 activity were determined using transient transfection and quantification of E2F target mRNAs by quantitative real-time PCR. The effect on cell cycle was assessed by fluorescence-activated cell sorting analysis on cells overexpressing green fluorescent protein-tagged RIP140. A tumor microarray data set was used to investigate the expression of RIP140 and E2F1 target genes in 170 breast cancer patients. RESULTS We first evidenced the complex interaction between RIP140 and E2F1 and showed that RIP140 represses E2F1 transactivation on various transiently transfected E2F target promoters and inhibits the expression of several E2F1 target genes (such as CCNE1 and CCNB2). In agreement with a role for RIP140 in the control of E2F activity, we show that increasing RIP140 levels results in a reduction in the proportion of cells in S phase in various human cell lines. Finally, analysis of human breast cancers shows that low RIP140 mRNA expression was associated with high E2F1 target gene levels and basal-like tumors. CONCLUSION This study shows that RIP140 is a regulator of the E2F pathway, which discriminates luminal- and basal-like tumors, emphasizing the importance of these regulations for a clinical cancer phenotype.
Collapse
Affiliation(s)
- Aurélie Docquier
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
| | | | | | | | | | | |
Collapse
|
8
|
Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15:5092-100. [PMID: 19671842 DOI: 10.1158/1078-0432.ccr-08-3283] [Citation(s) in RCA: 186] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE To investigate the clinical relevance of the recently characterized human oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) in human breast cancer. EXPERIMENTAL DESIGN CIP2A expression (mRNA and protein) was measured in three different sets of human mammary tumors and compared with clinicopathologic variables. The functional role of CIP2A in breast cancer cells was evaluated by small interfering RNA-mediated depletion of the protein followed by an analysis of cell proliferation, migration, anchorage-independent growth, and xenograft growth. RESULTS CIP2A mRNA is overexpressed (n = 159) and correlates with higher Scarff-Bloom-Richardson grades (n = 251) in samples from two independent human breast cancer patients. CIP2A protein was found to be overexpressed in 39% of 33 human breast cancer samples. Furthermore, CIP2A mRNA expression positively correlated with lymph node positivity of the patients and with the expression of proliferation markers and p53 mutations in the tumor samples. Moreover, CIP2A protein expression was induced in breast cancer mouse models presenting mammary gland-specific depletion of p53 and either BRCA1 or BRCA2. Functionally, CIP2A depletion was shown to inhibit the expression of its target protein c-Myc. Loss of CIP2A also inhibited anchorage-independent growth in breast cancer cells. Finally, CIP2A was shown to support MDA-MB-231 xenograft growth in nude mice. CONCLUSIONS Our data show that CIP2A is associated with clinical aggressivity in human breast cancer and promotes the malignant growth of breast cancer cells. Thus, these results validate the role of CIP2A as a clinically relevant human oncoprotein and warrant further investigation of CIP2A as a therapeutic target in breast cancer treatment.
Collapse
Affiliation(s)
- Christophe Côme
- Centre for Biotechnology, University of Turku, Turku, Finland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Cavailles V, Harmand P, Augereau P, Badia E, Docquier A, Ambit A, Chanrion M, Darbon J, Parker M, Fritsch S. The transcriptional repressor RIP140 is a cell-cycle regulated gene which controls E2F1 activity and cell proliferation. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71304-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
10
|
Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14:1744-52. [PMID: 18347175 DOI: 10.1158/1078-0432.ccr-07-1833] [Citation(s) in RCA: 138] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE The identification of a molecular signature predicting the relapse of tamoxifen-treated primary breast cancers should help the therapeutic management of estrogen receptor-positive cancers. EXPERIMENTAL DESIGN A series of 132 primary tumors from patients who received adjuvant tamoxifen were analyzed for expression profiles at the whole-genome level by 70-mer oligonucleotide microarrays. A supervised analysis was done to identify an expression signature. RESULTS We defined a 36-gene signature that correctly classified 78% of patients with relapse and 80% of relapse-free patients (79% accuracy). Using 23 independent tumors, we confirmed the accuracy of the signature (78%) whose relevance was further shown by using published microarray data from 60 tamoxifen-treated patients (63% accuracy). Univariate analysis using the validation set of 83 tumors showed that the 36-gene classifier is more efficient in predicting disease-free survival than the traditional histopathologic prognostic factors and is as effective as the Nottingham Prognostic Index or the "Adjuvant!" software. Multivariate analysis showed that the molecular signature is the only independent prognostic factor. A comparison with several already published signatures demonstrated that the 36-gene signature is among the best to classify tumors from both training and validation sets. Kaplan-Meier analyses emphasized its prognostic power both on the whole cohort of patients and on a subgroup with an intermediate risk of recurrence as defined by the St. Gallen criteria. CONCLUSION This study identifies a molecular signature specifying a subgroup of patients who do not gain benefits from tamoxifen treatment. These patients may therefore be eligible for alternative endocrine therapies and/or chemotherapy.
Collapse
Affiliation(s)
- Maïa Chanrion
- U868 Institut National de la Sante et de la Recherche Medicale, Tumoral Identity and Plasticity, Cancer Research Center of Montpellier, Université Montpellier 1, CRLC Val d'Aurelle-Paul Lamarque, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|